DGAP-News: 4basebio AG: Expedeon AG completes change of name to 4basebio AG and of ticker symbol to 4BSB

PRESS RELEASE
21 January 2020

Expedeon AG completes change of name to 4basebio AG and of ticker symbol to 4BSB

- Share is now traded under new ticker symbol 4BSB. WKN and ISIN remain.

- New name reflects repositioning on DNA manufacturing

Heidelberg, Germany and Cambridge, UK, 21 January 2020 - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) today announced that the Company has completed the name change from Expedeon AG to 4basebio AG. The Company's shares continue to be listed on the Regulated Market of the Frankfurt Stock Exchange's Prime Standard but will change ticker symbol to 4BSB effective as of today. The German securities identification code (WKN) and ISIN will remain unchanged (ISIN: DE000A2YN801, WKN: A2YN80).

The new name 4basebio reflects the new strategic focus of the Company on the manufacturing of DNA products. The name change was part of the 120 million Euro deal with Abcam plc for the sale of the proteomic and immunology business of Expedeon AG, which was approved by the Extraordinary General Meeting held on 19 December 2019. The entry of the name change in the Mannheim commercial register is effective.

About 4basebio AG: www.investors.4basebio.com

4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on January 1 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company will focus on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

4basebio AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).

For further information, please contact:

4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: [email protected]
Investors' information: investors.4basebio.com

MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone: +49 89 210228 0
Email: [email protected]

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###